Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort.
Antinori A, Marchetti G, Esposito V, Rusconi S, Canetti D, Quiros-Roldan E, Candelaresi B, Saracino A, Andreoni M, Marongiu A, Cassidy T, Thorpe D, Albini L, Caldera R, Forcina G, Di Perri G. Antinori A, et al. Among authors: rusconi s. Int J STD AIDS. 2025 Jan 8:9564624241308372. doi: 10.1177/09564624241308372. Online ahead of print. Int J STD AIDS. 2025. PMID: 39772928 Free article.
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry.
Clemente T, Diotallevi S, Minisci D, Di Biagio A, Lolatto R, Attala L, Cenderello G, Siribelli A, Muccini C, Lo Caputo S, Tavio M, Papaioannu Borjesson R, Giacomelli A, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. J Antimicrob Chemother. 2024 Dec 27:dkae465. doi: 10.1093/jac/dkae465. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39727173
Use of ICD-9-CM coding for identifying antibiotic prescriptions during hospitalization: a Delphi consensus model.
Comelli A, Genovese C, Renisi G, Scudeller L, Zanforlini M, Macaluso G, Mazzone A, Muscatello A, Bozzi G, Zoncada A, Pan A, Rossi M, Bonfanti P, Chiappetta S, Casari S, Ripa M, Castagna A, Signorini L, Castelli F, Chiamenti M, Marchetti GC, Castiglioni B, Franzetti F, Graziano E, Grossi P, Morelli P, Bartoletti M, Molteni C, Piconi S, Merli M, Puoti M, Ricaboni D, Pusterla L, Cerri C, Regazzetti A, Soavi L, Rizzi M, Franzetti M, Rusconi S, Asperges E, Bruno R, Schiavini M, Gori A, Schiatti S, Bandera A. Comelli A, et al. Among authors: rusconi s. Infect Prev Pract. 2024 Oct 28;6(4):100416. doi: 10.1016/j.infpip.2024.100416. eCollection 2024 Dec. Infect Prev Pract. 2024. PMID: 39691840 Free PMC article.
Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naïve and ART-experienced people with HIV in real-world setting: Data from the Icona cohort.
d'Arminio Monforte A, Tavelli A, Quiros-Roldan E, Fabbiani M, Ferrara M, Lo Caputo S, Squillace N, Rusconi S, Ponzano M, Bovis F, Antinori A, Saracino A, Cozzi-Lepri A. d'Arminio Monforte A, et al. Among authors: rusconi s. HIV Med. 2024 Dec 2. doi: 10.1111/hiv.13740. Online ahead of print. HIV Med. 2024. PMID: 39618291
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort.
Ciccullo A, Baldin G, Cervo A, Moschese D, Lagi F, Cossu MV, Grimaldi A, Giacomelli A, Rusconi S, Sterrantino G, Borghetti A, Antinori S, Mussini C, Di Giambenedetto S. Ciccullo A, et al. Among authors: rusconi s. J Antimicrob Chemother. 2025 Jan 3;80(1):175-177. doi: 10.1093/jac/dkae392. J Antimicrob Chemother. 2025. PMID: 39478330
Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort.
Soria A, Graziano F, Ghilardi G, Lapadula G, Gasperina DD, Benatti SV, Quiros-Roldan E, Milesi M, Bai F, Merli M, Minisci D, Franzetti M, Asperges E, Chiabrando F, Pocaterra D, Pandolfo A, Zanini F, Lombardi D, Cappelletti A, Rugova A, Borghesi ML, Squillace N, Pusterla L, Piconi S, Morelli P, Querini PR, Bruno R, Rusconi S, Casari S, Bandera A, Franzetti F, Travi G, D'Arminio Monforte A, Marchetti G, Pan A, Castelli F, Rizzi M, Dentali F, Mallardo M, Rossi E, Valsecchi MG, Galimberti S, Bonfanti P. Soria A, et al. Among authors: rusconi s. Heliyon. 2024 Aug 13;10(16):e36102. doi: 10.1016/j.heliyon.2024.e36102. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39247344 Free PMC article.
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.
Cingolani A, Tavelli A, De Benedittis S, Mastrorosa I, Muccini C, Bini T, Carraro A, Compagno M, Mazzitelli M, Guastavigna M, Cernuschi M, Torti C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study group. Cingolani A, et al. J Antimicrob Chemother. 2024 Oct 1;79(10):2662-2667. doi: 10.1093/jac/dkae273. J Antimicrob Chemother. 2024. PMID: 39140512
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Armenia D, Spagnuolo V, Bellocchi MC, Galli L, Duca L, Marchegiani G, Clemente T, Carioti L, Lolatto R, Calza L, Celesia BM, Cascio A, Francisci D, Saracino A, Torti C, Zazzi M, Castagna A, Santoro MM; PRESTIGIO Study Group. Armenia D, et al. J Antimicrob Chemother. 2024 Sep 3;79(9):2354-2363. doi: 10.1093/jac/dkae236. J Antimicrob Chemother. 2024. PMID: 39004997
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry.
Mazzitelli M, Pontillo D, Clemente T, Di Biagio A, Cenderello G, Rusconi S, Menzaghi B, Fornabaio C, Garlassi E, Zazzi M, Castagna A, Cattelan AM; PRESTIGIO Study Group. Mazzitelli M, et al. Among authors: rusconi s. J Antimicrob Chemother. 2024 Sep 3;79(9):2163-2169. doi: 10.1093/jac/dkae190. J Antimicrob Chemother. 2024. PMID: 39001781
434 results